CN110105402B - Berberine antitumor platinum (II) complex and synthesis method and application thereof - Google Patents
Berberine antitumor platinum (II) complex and synthesis method and application thereof Download PDFInfo
- Publication number
- CN110105402B CN110105402B CN201910495354.0A CN201910495354A CN110105402B CN 110105402 B CN110105402 B CN 110105402B CN 201910495354 A CN201910495354 A CN 201910495354A CN 110105402 B CN110105402 B CN 110105402B
- Authority
- CN
- China
- Prior art keywords
- complex
- berberine
- platinum
- tfa
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 title claims abstract description 28
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 26
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 229940093265 berberine Drugs 0.000 title claims abstract description 23
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 title claims abstract description 23
- 238000001308 synthesis method Methods 0.000 title abstract description 3
- 239000003814 drug Substances 0.000 claims abstract description 9
- 206010005003 Bladder cancer Diseases 0.000 claims description 6
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 6
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 abstract description 39
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract description 37
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 abstract description 18
- 239000003446 ligand Substances 0.000 abstract description 17
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 238000006243 chemical reaction Methods 0.000 abstract description 13
- 229910052697 platinum Inorganic materials 0.000 abstract description 7
- 230000005918 in vitro anti-tumor Effects 0.000 abstract description 6
- 239000002246 antineoplastic agent Substances 0.000 abstract description 5
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 5
- 238000010189 synthetic method Methods 0.000 abstract description 5
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 abstract description 4
- 239000002904 solvent Substances 0.000 abstract description 4
- 230000008685 targeting Effects 0.000 abstract description 4
- 238000001035 drying Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 230000005917 in vivo anti-tumor Effects 0.000 abstract description 3
- 229910052700 potassium Inorganic materials 0.000 abstract description 3
- 239000011591 potassium Substances 0.000 abstract description 3
- -1 potassium halide Chemical class 0.000 abstract description 3
- 238000005406 washing Methods 0.000 abstract description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 21
- 239000000243 solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 239000000047 product Substances 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000001228 spectrum Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 4
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 3
- 238000000921 elemental analysis Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000004293 19F NMR spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 241000123862 Fibraurea recisa Species 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229910019032 PtCl2 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000003832 berberine derivatives Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000000006 cell growth inhibition assay Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 150000004696 coordination complex Chemical class 0.000 description 1
- HPYNZHMRTTWQTB-UHFFFAOYSA-N dimethylpyridine Natural products CC1=CC=CN=C1C HPYNZHMRTTWQTB-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 150000002910 rare earth metals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
- C07F15/0086—Platinum compounds
- C07F15/0093—Platinum compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a berberine antitumor platinum (II) complex, a synthesis method thereof and application of the complex in preparing antitumor drugs. The synthetic method of the berberine antitumor platinum (II) complex comprises the following steps: (1) dissolving bromo-berberine derivative, potassium halide and dimethyl pyridylamine in a solvent, and reacting at 90 ℃ to obtain a B-TFA ligand; (2) and (2) dissolving the B-TFA ligand prepared in the step (1) and dichloro-bis (dimethyl sulfoxide) platinum (II) in an acetonitrile solution, carrying out coordination reaction for 4-6 hours, and washing and drying a product to obtain the compound. The invention synthesizes the platinum complex by taking the bromo-berberine derivative B-TFA as an active ligand for the first time, shows excellent in-vivo and in-vitro anti-tumor activity and targeting property, has potential medicinal value and is expected to be used for preparing various anti-tumor medicaments. The structural formula of the berberine anti-tumor platinum (II) complex is as follows:
Description
Technical Field
The invention relates to a platinum high-activity complex and a synthetic method thereof, in particular to a berberine anti-tumor platinum (II) complex and a synthetic method thereof. The invention also relates to the application of the berberine antitumor platinum (II) complex in preparing antitumor drugs.
Background
Since cisplatin was discovered, 4 anticancer drugs of nedaplatin, oxaliplatin, sulplatin and leplatin were listed in succession, but it was still unsatisfactory in improving the therapeutic effect, reducing the toxic and side effects and overcoming the cross-resistance. Scientists and researchers have tried to synthesize a new platinum antitumor complex by performing various structural modifications on platinum, and hopefully, the attempts have led to finding a platinum anticancer drug with higher activity and lower toxicity.
The main chemical component of the fibraurea recisa pierre is fibraurea recisa pierre alkaloid which is mainly distributed in areas such as Guangxi, Yunnan and Guangdong, and is one of the main sources of berberine or berberine. At present, berberine is verified to have the effects of anti-tumor, anti-inflammatory, antibacterial, immunity enhancement, nerve protection, anti-depression activity, blood fat reduction and the like. Hitherto, no related reports exist on the research of synthesizing the metal complex and the action mechanism thereof by taking berberine derivatives as the ligands of the active ingredients of the traditional Chinese medicine. Therefore, designing and searching the berberine anti-tumor rare earth metal complex with high water solubility, high curative effect, low toxic and side effects and strong targeting becomes a problem to be solved at present.
Disclosure of Invention
The first object of the present invention is to provide a berberine anti-tumor platinum (II) complex.
In order to achieve the first object of the present invention, the present invention provides the following technical solutions:
a berberine anti-tumor platinum (II) complex has the following chemical structural formula:
the second purpose of the invention is to provide a synthetic method of a berberine anti-tumor platinum (II) complex.
In order to achieve the second object of the present invention, the present invention provides the following technical solutions:
a synthetic method of a berberine anti-tumor platinum (II) complex comprises the following steps:
(1) dissolving bromo-berberine derivative, potassium halide and dimethyl pyridylamine in a solvent, and reacting at 90 ℃ to obtain a B-TFA ligand;
(2) and (2) dissolving the B-TFA ligand prepared in the step (1) and dichloro-bis (dimethyl sulfoxide) platinum (II) in an acetonitrile solution, carrying out coordination reaction for 4-6 hours, and washing and drying a product to obtain the compound.
Further, the solvent in the step (1) is acetonitrile.
Further, the molar ratio of the bromo-berberine derivative to the potassium halide to the dimethyl pyridylamine is 1:0.8: 1.5-3.2.
Further, the method is characterized in that the reaction time of the step (1) is 12-15 hours.
Further, the reaction temperature of the step (2) is 55-65 ℃.
Further, the volume of the acetonitrile solution in the step (2) is 10-75 mL.
The third purpose of the invention is to provide the application of the berberine antitumor platinum (II) complex in preparing antitumor drugs.
Compared with the prior art, the invention has the beneficial effects that:
1. the invention firstly takes a bromo-berberine derivative B-TFA as an active ligand to synthesize the platinum complex [ Pt (B-TFA) Cl ] Cl (wherein TFA is trifluoroacetic acid), and the synthesis route is simple, the reaction condition is mild, and the yield is high.
2. The invention researches the activity and toxicity experiments of the complex on T-24, SK-OV-3/DDP, A549 tumor cells and normal HL-7702 cells. Experimental results show that the complex has good inhibition effect on human tumor cells, and the IC50 value is 0.1-15.2 mu M; particularly, the compound has better inhibiting effect on human bladder cancer cell T-24, the IC50 values are 0.1 +/-0.1 mu M respectively, and the in vitro anti-tumor activity of the compound is far greater than that of a clinical classical metal-based anti-cancer medicament cisplatin 10.4 +/-1.2 mu M.
3. The berberine anti-tumor platinum (II) complex and the Pt1 complex have little toxicity (IC50 is more than 150 mu M) to normal cells HL-7702, and show good effect of targeted inhibition of proliferation of human bladder cancer cells. In a word, the complex Pt1 shows excellent in-vivo and in-vitro anti-tumor activity and targeting property, has potential medicinal value and is expected to be used for preparing various anti-tumor medicaments.
4. When the berberine antitumor platinum (II) complex is synthesized, the reaction can be carried out only if the mass ratio of the bromo-berberine derivative to the dimethyl pyridylamine is 1: 1.5-3.2; the reaction temperature is 90 ℃, the product is adhered to the bottom and generates carbon chain breakage at the temperature higher than 90 ℃, and the reaction hardly occurs at the temperature lower than 90 ℃.
Drawings
The technical solutions of the present invention are further described in detail with reference to the specific embodiments in the drawings, but the present invention is not limited thereto.
FIG. 1 is an electrospray mass spectrum of B-TFA prepared in example 1 of the present invention;
FIG. 2 is a hydrogen nuclear magnetic resonance spectrum of B-TFA obtained in example 1 of the present invention;
FIG. 3 is a nuclear magnetic resonance carbon spectrum of B-TFA obtained in example 1 of the present invention;
FIG. 4 is a nuclear magnetic resonance fluorine spectrum of B-TFA obtained in example 1 of the present invention;
FIG. 5 is an electrospray mass spectrum of a complex Pt1 prepared in example 1 of the present invention;
FIG. 6 is a NMR spectrum of Pt1 obtained in example 1 of the present invention;
FIG. 7 is a NMR carbon spectrum of Pt1 obtained in example 1 of the present invention;
FIG. 8 shows the nuclear magnetic resonance fluorine spectrum of Pt1 obtained in example 1 of the present invention.
Detailed Description
The raw material bromo-berberine derivative 1 related in the embodiment of the invention is prepared by referring to the existing literature (Huang, Z. -S.; et al. bioorgan. Med. chem.,2008,16, 7582-7591.); in addition, platinum (II) bis (dimethyl sulfoxide) dichloride can be prepared by referring to the existing literature (Al-Allaf, T.A.K.; et Al. Transit. Met. chem.,1998,23:403-406.) which is abbreviated as cis-PtCl2(DMSO)2。
Example 1
1.0mol of derivative 1, 0.8mol of potassium iodide and 3.20mol of lutidine are respectively weighed in a high-temperature pressure-resistant tube, 5.0ml of acetonitrile is added, the added solvent is just finished to dissolve the solid, so that the reaction is more complete, and after the reaction is carried out for 12 hours at 90 ℃, yellow solid powder B-TFA ligand is obtained, wherein the yield is 94.0%.
Weighing 1.0mol of ligand B-TFA and 1.0mol of dichloro-bis (dimethyl sulfoxide) platinum (II), placing the ligand B-TFA and 1.0mol of dichloro-bis (dimethyl sulfoxide) platinum (II) into a 100.0mL high-temperature pressure-resistant bottle, adding 25.0mL of acetonitrile solution, carrying out coordination reaction at 60 ℃ for 4.0h, washing with acetonitrile, and drying in vacuum at 45 ℃ to obtain a yellow target product Pt 1. The yield was 90.8%.
The synthetic route of the berberine anti-tumor platinum (II) complex is as follows:
example 2
The difference from example 1 is that ligand B-TFA (1.0mol) and platinum (II) bis (dimethyl sulfoxide) (1.0mol) dichloride are weighed and placed in a 100.0mL high-temperature pressure-resistant bottle, 10.0mL of acetonitrile solution is added, coordination reaction is carried out for 4.0h at 60 ℃, the solution is washed by acetonitrile and dried in vacuum at 45 ℃, and then the yellow target product Pt1 is obtained. The yield was 85.6%.
Example 3
The difference from example 1 is that ligand B-TFA (1.0mol) and platinum (II) bis (dimethyl sulfoxide) (1.0mol) dichloride are weighed and placed in a 100.0mL high-temperature pressure-resistant bottle, 75.0mL of acetonitrile solution is added, coordination reaction is carried out for 4.0h at 60 ℃, the solution is washed by acetonitrile and dried in vacuum at 45 ℃, and then the yellow target product Pt1 is obtained. The yield was 80.0%.
Example 4
The difference from example 1 is that ligand B-TFA (1.0mol) and dichloro-bis (dimethyl sulfoxide) platinum (II) (1.0mol) are weighed and placed in a 100.0mL high-temperature pressure-resistant bottle, 40.0mL of acetonitrile solution is added, coordination reaction is carried out for 4.0h at 60 ℃, the solution is washed by acetonitrile and then dried in vacuum at 45 ℃, and then yellow target product Pt1 is obtained. The yield was 89.1%.
Experimental example 1
To further determine the structure of the ligands and complexes, the structure of the product of example 1 was characterized.
1. Identification of the resulting B-TFA
(1) Electrospray mass spectrometry, the spectrum of which is shown in figure 1.
ESI-MS M/z 645.3[ M- (TFA-H) ] +, where M is the molecular weight of Compound B-TFA.
(2) The NMR spectrum is shown in FIG. 2.
1H NMR(400MHz,CHCl3-d)δ9.84(s,1H),8.81(d,J=5.5Hz,2H),8.26-8.20(m,2H),8.20-8.16(m,1H),7.87(dd,J=4.7,8.3Hz,3H),7.82-7.76(m,1H),7.67(t,J=6.5Hz,2H),7.36(s,1H),6.85(s,1H),6.11(s,2H),5.01(br t,J=5.8Hz,2H),4.42(s,4H),4.36(t,J=6.7Hz,2H),4.06(s,3H),3.29-3.20(m,2H),2.87-2.77(m,2H),1.93-1.82(m,2H),1.65-1.52(m,2H),1.48-1.39(m,2H),1.34-1.29(m,2H),1.23(br s,6H)。
(3) NMR spectrum of carbon, as shown in FIG. 3.
13C NMR(400MHz,DMSO-d6)δ158.925-158.561(m,2C),150.810(s,1C),150.416-149.847(m,1C),149.001(s,2C),147.711(s,1C),145.275(s,1C),142.927(s,1C),137.889-137.473(s,2C),130.648(s,1C),126.674(s,1C),124.990(s,1C),124.122(s,1C),123.306(s,1C),121.687(s,1C),120.447(s,1C),120.236(s,1C),117.399(s,1C),114.490(s,1C),108.380(s,1C),105.426(s,1C),102.080(s,1C),74.265(s,1C),56.981-56.769(m,3C),55.318(s,1C),53.926(s,1C),29.469(s,1C),28.711–28.390(m,2C),26.363(s,1C),25.904(s,1C),25.226(s,1C),23.191(s,1C)。
(4) NMR spectrum of fluorine as shown in FIG. 3.
19F NMR(471MHz,CHCl3)δ-75.804。
(5) The results of elemental analysis are shown in Table 1.
Table 1 elemental analysis results of Compounds B-TFA and Pt1 in the examples
Thus, the yellow target product was identified as compound B-TFA, having the formula:
2. the obtained complex Pt1 is identified
(1) Electrospray mass spectrometry, the spectrum of which is shown in FIG. 5.
ESI-MS m/z:987.4[M-Cl]+Wherein M is the molecular weight of the complex Pt 1.
(2) The NMR spectrum is shown in FIG. 6.
1H NMR(500MHz,DMSO-d6)δ9.72(s,1H),8.92(s,1H),8.77(d,J=5.3Hz,2H),8.31(t,J=7.2Hz,2H),8.23–8.09(m,1H),7.99(s,1H),7.85(s,2H),7.75(s,1H),7.67(t,J=6.6Hz,2H),7.08(s,1H),6.18(s,2H),5.37(s,2H),4.94(d,J=31.1Hz,4H),4.24(t,J=6.4Hz,2H),4.04(s,3H),3.05(s,2H),2.52(s,2H),1.90-1.75(m,2H),1.51(s,2H),1.40(t,J=7.9Hz,2H),1.31–1.20(m,4H),1.16(d,J=14.4Hz,4H)。
(3) NMR spectrum of carbon, as shown in FIG. 7.
13C NMR(126MHz,DMSO-d6)δ166.31,158.44,158.19,150.84,150.23,149.43,148.10,145.73,143.29,141.82,137.85,133.44,131.07,127.07,125.85,123.99,123.82,122.10,120.88,120.70,108.89,105.86,102.57,74.72,68.50,64.81,57.53,55.84,40.56,40.39,40.23,40.06,39.89,39.72,39.56,29.93,29.25,29.10,29.03,27.58,26.86,26.31,25.64。
(4) NMR spectrum of the product shown in FIG. 8.
19F NMR(471MHz,DMSO-d6)δ-73.52。
(5) The results of elemental analysis are shown in Table 1.
Thus, the resulting yellow target product was identified as complex Pt1, having the formula:
experimental example 2
In order to fully illustrate the application of the berberine antitumor platinum (II) complex Pt1 in pharmacy, in-vivo and in-vitro antitumor activity experiments are carried out on the berberine antitumor platinum (II) complex.
Experiment on proliferation inhibition activity of platinum (II) complex Pt1 on various human tumor cell lines
1. Cell lines and cell cultures
4 human cell strains such as human ovarian cancer cisplatin-resistant SK-OV-3/DDP cells, human bladder cancer T-24 cells, human bladder cancer A549 cells, human normal liver HL-7702 cells and the like are selected for the experiment.
All human cell lines were cultured in RPMI-1640 medium containing 100U/mL penicillin, 10 wt% calf blood, and 100U/mL streptomycin, and placed at 37 deg.C with 5% CO by volume2Culturing in an incubator.
2. Preparation of test Compounds
The ligands B-TFA and Pt1 used were all 95% pure, their DMSO stock solutions were diluted with physiological buffer to 20. mu. mol/L final solution (DMSO final concentration. ltoreq.1%) at which the degree of inhibition of growth of normal cells or selected tumor cells by each compound was tested.
3. Cell growth inhibition assay (MTT method)
(1) Taking normal cells or tumor cells in a logarithmic growth phase, digesting the cells or tumor cells by trypsin, preparing a cell suspension with the concentration of 5000/mL by using a culture solution containing 10% calf serum, inoculating 190 mu L of the cell suspension into a 96-hole culture plate, and enabling the density of cells to be detected to reach 1000-10000 holes (the edge holes are filled with sterile PBS);
(2)5%CO2incubating for 24h at 37 ℃ until a cell monolayer is paved on the bottom of each well, adding 10 mu L of medicine with a certain concentration gradient into each well, and arranging 4 compound wells in each concentration gradient;
(3)5%CO2incubating at 37 ℃ for 48 hours, and observing under an inverted microscope;
(4) add 10. mu.L of MTT solution (5mg/mL PBS, i.e., 0.5% MTT) to each well and continue culturing for 4 h;
(5) terminating the culture, carefully removing the culture solution in the wells, adding 150 μ L of DMSO into each well to sufficiently dissolve formazan precipitate, mixing uniformly with an oscillator, and measuring the optical density of each well with a microplate reader at a wavelength of 570nm and a reference wavelength of 450 nm;
(6) simultaneously, a zero setting hole (culture medium, MTT, DMSO) and a control hole (cells, culture solution, MTT, a drug dissolving medium with the same concentration, DMSO) are arranged.
(7) The number of living cells was judged from the measured optical density values (OD values), and the larger the OD value, the stronger the cell activity. Using the formula:
calculating the inhibition rate of each compound on the growth of the selected cells, and calculating the IC of each tested compound on each selected cell strain by a Bliss method50The value is obtained. The results are shown in table 2 below.
TABLE 2 IC of Compounds on various cell lines50Value (μ M)
Slave IC50According to the result of activity screening, the proliferation inhibition activity of the complex Pt1 on three tested human tumor cell strains SK-OV-3/DDP, T-24 and A549 cells is obviously higher than that of cis-Pt (DMSO) of metal salt2Cl2And ligands B-TFA and TFA thereof, which embody the synergistic effect of ligand B-TFA and a platinum central atom. Wherein the complex Pt1 has better inhibiting effect on T-24 cells and IC thereof50The value is 0.1 +/-0.1 mu M, and the in vitro anti-tumor activity of the compound is far greater than that of a clinical classical metal-based anti-cancer medicament cisplatin (10.4 +/-1.2 mu M); furthermore, the Pt1 complex has little toxicity (IC) to HL-7702 which is a normal cell50The value is more than 150 mu M), and the compound shows good effect of targeted inhibition of bladder cancer cell proliferation. In a word, the complex Pt1 shows excellent in-vitro anti-tumor activity and targeting selectivity on tumor cells, has potential medicinal value and is expected to be used for preparing various anti-tumor medicaments.
The above description is part of the embodiments of the present invention, and is not intended to limit the present invention. It will be apparent to those skilled in the art that various modifications and variations can be made without departing from the principles of the invention.
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910495354.0A CN110105402B (en) | 2019-06-10 | 2019-06-10 | Berberine antitumor platinum (II) complex and synthesis method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910495354.0A CN110105402B (en) | 2019-06-10 | 2019-06-10 | Berberine antitumor platinum (II) complex and synthesis method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110105402A CN110105402A (en) | 2019-08-09 |
CN110105402B true CN110105402B (en) | 2021-09-07 |
Family
ID=67494374
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910495354.0A Active CN110105402B (en) | 2019-06-10 | 2019-06-10 | Berberine antitumor platinum (II) complex and synthesis method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110105402B (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108659051A (en) * | 2018-05-07 | 2018-10-16 | 玉林师范学院 | A kind of high activity cumarin targeting oophoroma-platinum (II) complex and its synthetic method and application |
CN108774270A (en) * | 2018-07-20 | 2018-11-09 | 玉林师范学院 | Target Sorafenib anti-tumor platinum (II) complex and the preparation method and application thereof of human lung cancer mdr cell |
CN108774269A (en) * | 2018-07-20 | 2018-11-09 | 玉林师范学院 | Novel targeted benzimidazoles derivative anti-tumor platinum (II) and ruthenium (II) complex and the preparation method and application thereof |
-
2019
- 2019-06-10 CN CN201910495354.0A patent/CN110105402B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108659051A (en) * | 2018-05-07 | 2018-10-16 | 玉林师范学院 | A kind of high activity cumarin targeting oophoroma-platinum (II) complex and its synthetic method and application |
CN108774270A (en) * | 2018-07-20 | 2018-11-09 | 玉林师范学院 | Target Sorafenib anti-tumor platinum (II) complex and the preparation method and application thereof of human lung cancer mdr cell |
CN108774269A (en) * | 2018-07-20 | 2018-11-09 | 玉林师范学院 | Novel targeted benzimidazoles derivative anti-tumor platinum (II) and ruthenium (II) complex and the preparation method and application thereof |
Non-Patent Citations (1)
Title |
---|
Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1;Yane Xiang Wang et al.;《European Journal of Medicinal Chemistry》;20171111;1858-1868页 * |
Also Published As
Publication number | Publication date |
---|---|
CN110105402A (en) | 2019-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107746418B (en) | Synthesis and application of 9-chloro-1, 2,3, 4-tetrahydroacridine-platinum (II) complex targeting liver cancer | |
CN108774270B (en) | Sorafenib antitumor platinum (II) complex targeting drug-resistant cells of human lung cancer and preparation method and application thereof | |
CN110950914B (en) | Iridium complex and synthesis method and application thereof | |
CN111187303B (en) | Platinum (II) complex with high antitumor activity of cryptolepine, and synthetic method and application thereof | |
CN110054652B (en) | Jatrorrhizine platinum (II) complex and synthesis method and application thereof | |
CN111039990B (en) | Low-toxicity iridium complex and synthesis method and application thereof | |
CN108774269B (en) | Novel targeted benzimidazole derivative antitumor platinum (II) and ruthenium (II) complex and preparation method and application thereof | |
CN111153916A (en) | White leaf vine zinc (II) complex and synthesis method and application thereof | |
CN111205311A (en) | Novel high-antitumor-activity white leaf vine zinc (II) complex and synthesis method and application thereof | |
CN110330534B (en) | Novel 2-phenylpyridine-platinum (IV) precursor anticancer complex and synthesis method and application thereof | |
CN111253418A (en) | Novel white leaf vine zinc (II) complex and synthesis method and application thereof | |
CN111116667B (en) | Iridium complex constructed based on 8-hydroxyquinoline derivative and 1-phenylpyrazole iridium dimer as well as synthetic method and application thereof | |
CN110105402B (en) | Berberine antitumor platinum (II) complex and synthesis method and application thereof | |
CN114539294B (en) | Cisplatin-resistant cell white rattan-phenanthrene Luo Linxin (II) complex for targeting human lung adenocarcinoma, synthesis method and application thereof | |
CN110172075B (en) | Novel coumarin-quinoline-platinum (II) complex and synthesis method and application thereof | |
CN114573598B (en) | White She Tengxin (II) complex with high in-vivo and in-vitro activity and synthesis method and application thereof | |
CN107827934B (en) | Tetravalent platinum complex with anticancer activity, preparation method and application | |
CN110054651B (en) | Targeted human bladder cancer jatrorrhizine platinum (II) complex and synthesis method and application thereof | |
CN108997436B (en) | Rueglini antitumor platinum (II) complex and preparation method and application thereof | |
CN110156842B (en) | Coumarin-platinum (II) complex targeting lung cancer drug-resistant strain and synthesis method and application thereof | |
CN108456231B (en) | Bis-halo coumarin-platinum (II) complex and synthesis method and application thereof | |
CN114409707B (en) | 8-hydroxyquinoline-N-oxide manganese complex and synthetic method and application thereof | |
CN115385940B (en) | Zinc (II) complex of sinomenine and application thereof | |
CN115160347B (en) | Glycosyl white vine zinc (II) complex and application | |
CN117551136A (en) | 4-phenyl-2, 6-bis (2' -pyrazinyl) pyridine binuclear platinum complex, synthesis method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20190809 Assignee: Guangxi Xinghui Technology Co.,Ltd. Assignor: Yulin Normal University Contract record no.: X2022450000344 Denomination of invention: A Berberine Antitumor Platinum (II) Complex and Its Synthesis and Application Granted publication date: 20210907 License type: Common License Record date: 20221219 |
|
EE01 | Entry into force of recordation of patent licensing contract |